New technology for the delivery of peptide-based T-cell vaccines for tumour immunotherapy

The aim of this project is to develop specifically designed peptides and to incorporate them into a new delivery platform for use as vaccines in cancer. Critical to the success of this approach is our technology which stabilises these peptides against degradation in the body whilst maintaining their high level of potency. This work has the potential to protect animals and humans from a wide variety of cancers through treatment with relatively cheap, readily prepared peptides.